Vaccines (May 2022)

Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice

  • Challika Kaewborisuth,
  • Asawin Wanitchang,
  • Surapong Koonpaew,
  • Kanjana Srisutthisamphan,
  • Janya Saenboonrueng,
  • Rawiwan Im-Erbsin,
  • Manutsanun Inthawong,
  • Piyanate Sunyakumthorn,
  • Theeradej Thaweerattanasinp,
  • Nathiphat Tanwattana,
  • Yuparat Jantraphakorn,
  • Matthew C. Reed,
  • Luis A. Lugo-Roman,
  • Taweewun Hunsawong,
  • Chonticha Klungthong,
  • Anthony R. Jones,
  • Stefan Fernandez,
  • Samaporn Teeravechyan,
  • Eric D. Lombardini,
  • Anan Jongkaewwattana

DOI
https://doi.org/10.3390/vaccines10050786
Journal volume & issue
Vol. 10, no. 5
p. 786

Abstract

Read online

Virus-like particles (VLPs) are highly immunogenic and versatile subunit vaccines composed of multimeric viral proteins that mimic the whole virus but lack genetic material. Due to the lack of infectivity, VLPs are being developed as safe and effective vaccines against various infectious diseases. In this study, we generated a chimeric VLP-based COVID-19 vaccine stably produced by HEK293T cells. The chimeric VLPs contain the influenza virus A matrix (M1) proteins and the SARS-CoV-2 Wuhan strain spike (S) proteins with a deletion of the polybasic furin cleavage motif and a replacement of the transmembrane and cytoplasmic tail with that of the influenza virus hemagglutinin (HA). These resulting chimeric S-M1 VLPs, displaying S and M1, were observed to be enveloped particles that are heterogeneous in shape and size. The intramuscular vaccination of BALB/c mice in a prime-boost regimen elicited high titers of S-specific IgG and neutralizing antibodies. After immunization and a challenge with SARS-CoV-2 in K18-hACE2 mice, the S-M1 VLP vaccination resulted in a drastic reduction in viremia, as well as a decreased viral load in the lungs and improved survival rates compared to the control mice. Balanced Th1 and Th2 responses of activated S-specific T-cells were observed. Moderate degrees of inflammation and viral RNA in the lungs and brains were observed in the vaccinated group; however, brain lesion scores were less than in the PBS control. Overall, we demonstrate the immunogenicity of a chimeric VLP-based COVID-19 vaccine which confers strong protection against SARS-CoV-2 viremia in mice.

Keywords